| Name | Kroger Pharmacy # 943 |
|---|---|
| Organization Name | Kroger Limited Partnership I |
| Location | 1212 W Kemper Rd, Cincinnati, Ohio 45240 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (513) 742-2000 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
GNC Acquisition Holdings Inc. announced that, in connection with its previously announced initial public offering, the underwriters have exercised in full their option to purchase from the selling stockholders an additional 3.375 million shares of Class A common stock.
HealthSouth Corporation today announced it has entered into an agreement to purchase Cardinal Hill Rehabilitation Hospital in Lexington, Kentucky, from the Kentucky Easter Seal Society, Inc.
In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barre? syndrome after individuals were vaccinated against COVID-19.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 5 days ago
| NPI Number | 1962436766 |
| Organization Name | KROGER LIMITED PARTNERSHIP I |
| Doing Business As | KROGER PHARMACY |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 1212 W Kemper Rd, Cincinnati, OH 45240 |
| Phone Number | 513-742-2000 |
News Archive
GNC Acquisition Holdings Inc. announced that, in connection with its previously announced initial public offering, the underwriters have exercised in full their option to purchase from the selling stockholders an additional 3.375 million shares of Class A common stock.
HealthSouth Corporation today announced it has entered into an agreement to purchase Cardinal Hill Rehabilitation Hospital in Lexington, Kentucky, from the Kentucky Easter Seal Society, Inc.
In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barre? syndrome after individuals were vaccinated against COVID-19.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 5 days ago
News Archive
GNC Acquisition Holdings Inc. announced that, in connection with its previously announced initial public offering, the underwriters have exercised in full their option to purchase from the selling stockholders an additional 3.375 million shares of Class A common stock.
HealthSouth Corporation today announced it has entered into an agreement to purchase Cardinal Hill Rehabilitation Hospital in Lexington, Kentucky, from the Kentucky Easter Seal Society, Inc.
In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barre? syndrome after individuals were vaccinated against COVID-19.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
› Verified 5 days ago
Advanced Home Medical Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4460 Lake Forest Dr, Cincinnati, Ohio 45242 Phone: (614) 433-9011 | |
Advanced Orthotic Solutions Llc Type: Medicare Supplier Location: 5820 Ridge Ave, Cincinnati, Ohio 45213 Phone: (513) 628-2407 | |
Bernens Convalescent Pharmacy Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5053 Glenway Ave, Cincinnati, Ohio 45238 Phone: (513) 471-7575 | |
Biorx Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 7167 E. Kemper Rd., Cincinnati, Ohio 45249 Phone: (513) 792-7080 | |
Bio Works Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 7791 Cooper Rd, Cincinnati, Ohio 45242 Phone: (513) 793-7335 |